A new study has assured doctor and clients alike that common drugs for lowering blood pressure are not linked to an increased risk of COVID-19
On March 17, 2020, the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) released a joint statement prompting researchers to deal with particular spaces in our understanding of COVID-19 threat.
More particularly, the ACC, AHA, and HFSA pointed out a need to clarify whether or not individuals who have taken antihypertensive medication– that is, the drugs that help lower high blood pressure— are at higher threat of developing COVID-19 or experiencing a serious type of the illness.
According to the World Health Company (WHO), an estimated 1.13 billion individuals worldwide have high blood pressure (hypertension), which antihypertensive medications can assist manage.
If there was any sign that such drugs may contribute to a person’s danger of establishing COVID-19 or causing a severe kind of the illness, this would be deeply concerning for physician worldwide.
Just recently, private investigators from the NYU Grossman School of Medicine in New York City and teaming up organizations carried out a study that intended to settle this issue.
The research– which now appears in The New England Journal of Medicine— draws an encouraging conclusion: There is no association between the typical blood pressure drugs included in the research study and the threat of COVID-19
In their study, the researchers focused on a class of drugs called renin-angiotensin-aldosterone system inhibitors.
Especially, they looked at angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, and thiazide diuretics.
Researchers had been questioning the potential impact of ACE inhibitors on COVID-19 threat since they interact with the protein ACE2, which is associated with blood pressure guideline.
Nevertheless, current investigations h